Literature DB >> 9868407

[Last ICRU recommendations for the prescription, recording and reporting of external bean therapy].

J Chavaudra1.   

Abstract

Due to the evolution of radiotherapy techniques and equipment, in 1993 the ICRU decided to modify the guidelines that had been published in the ICRU report 29 (1978) in regard to photon beam therapy and to insert them in Report number 50 (1993). Changes that were introduced mainly concerned the prescription, recording and reporting of external beam therapy with photons. While awaiting for the upcoming publication of the report focusing on external beam therapy with electrons, the ICRU decided to publish a supplement to Report 50, as new insights had been gained after discussions with the Nordic Association of Clinical Physicists (NACP). This supplement includes the following: more accurate definitions of the margins allowing the planned target volume to be derived from the clinical target volume, the internal target volume, the expected volume of organs at-risk and the conformity index. All three points will be included in the report focusing on external beam therapy with electrons as well as extensive discussions relating to the implementation of these new recommendations.

Entities:  

Mesh:

Year:  1998        PMID: 9868407     DOI: 10.1016/s1278-3218(98)80104-2

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  7 in total

1.  Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer.

Authors:  Hendrik A Wolff; Lena-Christin Conradi; Markus Schirmer; Tim Beissbarth; Thilo Sprenger; Margret Rave-Fränk; Steffen Hennies; Clemens F Hess; Heinz Becker; Hans Christiansen; Torsten Liersch
Journal:  Oncologist       Date:  2011-05-09

2.  High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.

Authors:  Hendrik Andreas Wolff; Jochen Gaedcke; Klaus Jung; Robert Michael Hermann; Hilka Rothe; Markus Schirmer; Torsten Liersch; Markus Karl Alfred Herrmann; Steffen Hennies; Margret Rave-Fränk; Clemens Friedrich Hess; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

3.  Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?

Authors:  Emmanouil Fokas; Ulrich Wacker; Markus W Gross; Martin Henzel; Elitsa Encheva; Rita Engenhart-Cabillic
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

4.  Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma: Effects on treatment-related side effects and survival.

Authors:  Hanne Elisabeth Weber; Leif Hendrik Dröge; Steffen Hennies; Markus Karl Herrmann; Jochen Gaedcke; Hendrik Andreas Wolff
Journal:  Strahlenther Onkol       Date:  2015-06-08       Impact factor: 3.621

5.  Single fraction radiosurgery using Rapid Arc for treatment of intracranial targets.

Authors:  Hendrik A Wolff; Daniela M Wagner; Hans Christiansen; Clemens F Hess; Hilke Vorwerk
Journal:  Radiat Oncol       Date:  2010-09-13       Impact factor: 3.481

6.  Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment.

Authors:  Lena-Christin Conradi; Annalen Bleckmann; Markus Schirmer; Thilo Sprenger; Peter Jo; Kia Homayounfar; Hendrik A Wolff; Hilka Rothe; Peter Middel; Heinz Becker; Michael B Ghadimi; Tim Beissbarth; Torsten Liersch
Journal:  Ann Surg Oncol       Date:  2011-02-23       Impact factor: 5.344

7.  The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer.

Authors:  Felix Rühlmann; Manuel Nietert; Thilo Sprenger; Hendrik A Wolff; Kia Homayounfar; Peter Middel; Hanibal Bohnenberger; Tim Beissbarth; B Michael Ghadimi; Torsten Liersch; Lena-Christin Conradi
Journal:  J Cancer       Date:  2017-04-10       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.